Investors / United Kingdom / Abingworth
Abingworth
Venture capital · London, United Kingdom · Europe
Abingworth is a life science investment firm that has been investing in biotechnology companies since 1987 and has invested in over 200 companies. It invests in private and public biopharma companies across seed and early stage, development stage, and clinical co-development strategies.
Invests inHealthcare & Biotech
In its own wordslife sciencesbiotechtherapeuticshealthcareclinical co-developmentpublic markets
Your fit with Abingworth
Four questions about your startup
See how your round matches what it backs, point by point.
Or find every investor that fitsAbingworth lists 21 checked portfolio companies on its own site and is named in 9 funding rounds, 1 of them as lead. Its most frequent entry is Series A, 50% of the companies with a known first round. Its largest themes are Healthcare & Biotech (91%), Fintech (5%) and AI & Machine Learning (5%). 88% of its companies are based in United States. It invests most often alongside SymBiosis Capital Management, Catalio Capital Management and Frazier Life Sciences.
Counts come from funding rounds that name Abingworth, complete from mid-2025: earlier rounds appear only when they were reported later. Round amounts and full round histories are on Fundup AI.
Round figures show recent activity, not Abingworth's whole history. Rounds on record name 9 companies; its own site lists 21. Funding rounds are complete from mid-2025, so counts and the yearly trend undercount a firm that invested before then. The portfolio, themes and places come from its own site and are not affected.
Entry stage
share of companies by the stage of its first roundShow as a table
| Value | |
|---|---|
| Pre-seed | 0% |
| Seed | 0% |
| Series A | 50% |
| Series B | 13% |
| Growth | 38% |
Activity by year
rounds it joined, last 10 yearsShow as a table
| Total | Rounds it led | |
|---|---|---|
| '17 | 0 | 0 |
| '18 | 0 | 0 |
| '19 | 0 | 0 |
| '20 | 0 | 0 |
| '21 | 0 | 0 |
| '22 | 0 | 0 |
| '23 | 0 | 0 |
| '24 | 0 | 0 |
| '25 | 5 | 0 |
| '26 | 4 | 1 |
Investor profile
percentile among all firmsShow as a table
| Measure | Percentile of all firms | Value |
|---|---|---|
| Portfolio size | 53th | 21 companies |
| Recent activity | 86th | 5 rounds in 12 months |
| Early stage | 54th | 0% of entries at pre-seed or seed |
| Evidence | 96th | 29% of companies confirmed by a round |
| Sector focus | 96th | 91% in its largest sector |
| Reach | 58th | 3 countries |
Invests most often with
firms sharing its portfolio companiesShow as a table
| Share | |
|---|---|
| SymBiosis Capital Management | 3 |
| Catalio Capital Management | 2 |
| Frazier Life Sciences | 2 |
| Lightstone Ventures | 2 |
| RA Capital | 2 |
| RiverVest Venture Partners | 2 |
| Sanofi Ventures | 2 |
| 4BIO Capital | 1 |
Its portfolio companies
where they are based, and what their own sites showSite status
- Site answers2095%
- No longer answers00%
- Points to another company15%
- Parked or sold domain00%
A site that stops answering three checks in a row is counted as no longer answering; that is not proof of closure. A site that points to another company is often an acquisition.
Investment themes
share of its checked companiesThis firmAll checked companies
Show as a table
| This firm | All checked companies | |
|---|---|---|
| Healthcare & Biotech | 91% | 15% |
| Fintech | 5% | 12% |
| AI & Machine Learning | 5% | 18% |
Co-investor network
who it backs companies with, and who they back togetherAll co-investors or Compare portfolios with SymBiosis Capital Management
Compare Abingworth head to head
portfolio size, rounds, entry stages, themes and the companies both backThree or more firms at once: portfolio overlap.
Funds
as stated on its siteRecent portfolio activity
when companies last raised with Abingworth| Date | Company | Stage |
|---|---|---|
| 15 Jul 2026 | Series C+ | |
| 20 May 2026 | Series A | |
| 5 May 2026 | Series A | |
| 17 Mar 2026 | Series A Led | |
| 17 Dec 2025 | Series A | |
| 17 Nov 2025 | Round | |
| 10 Nov 2025 | Series B | |
| 16 Apr 2025 | Series C+ |
Round details for Abingworth
Amounts, full round histories and every co-investor in Abingworth's rounds are on Fundup AI. VCinfo covers investors and their portfolios.
Portfolio
21 companies checked against their own sites| Company | What it does | Themes | First round with it | Evidence |
|---|---|---|---|---|
| Addition Therapeutics is advancing a pipeline of therapeutics to deliver functional cures for patients with severe lifelong diseases | Healthcare & Biotech | Dec 2025Series A | Funding round | |
| Addition Wealth provides personalized financial guidance to individuals, employers, and financial institutions using AI technology. | FintechAI & Machine Learning | Portfolio page | ||
| Adicet Bio develops gamma delta T cell therapies for patients with autoimmune diseases and cancer. | Healthcare & Biotech | Portfolio page | ||
| AdvanCell is a clinical-stage radiopharmaceutical company developing targeted alpha therapies for cancer treatment. | Healthcare & Biotech | Jul 2026Series C+ | Page + round | |
| The company develops allogeneic T-cell therapies for various indications, including T-cell cancers and autoimmune diseases. | Healthcare & Biotech | Portfolio page | ||
| Ascend Advanced Therapies supports the development of advanced therapies, including gene therapies, immunotherapies, oncolytics, and vaccines, from research to commercialization | Healthcare & Biotech | Portfolio page | ||
| Atsena Therapeutics is a clinical-stage gene therapy company developing treatments for inherited retinal diseases. | Healthcare & Biotech | Portfolio page | ||
| cAMPfield Therapeutics is a clinical-stage biopharmaceutical company developing oral medicines for inflammatory diseases | Healthcare & Biotech | May 2026Series A | Page + round | |
| Cytospire Therapeutics develops next generation immune cell engagers, including multispecific antibodies and gamma delta T cell engagers, for cancer therapies. | Healthcare & Biotech | May 2026Series A | Page + round | |
| Entact Bio creates new medicines by enhancing protein function | Healthcare & Biotech | Portfolio page | ||
| Glycomine is developing replacement therapies for rare genetic diseases | Healthcare & Biotech | Apr 2025Series C+ | Page + round | |
| Iambic Therapeutics develops medicines using artificial intelligence and molecular technologies | Healthcare & Biotech | Nov 2025Series B | Page + round | |
| Jasper Therapeutics is developing innovative therapies to treat significant immune-mediated diseases | Healthcare & Biotech | Portfolio page | ||
| Launch Tx provides biotech and biopharma companies with solutions that speed drug candidates' path to market and connection with investors that provide development funding. | Healthcare & Biotech | Portfolio page | ||
| Pathalys is developing therapeutics to improve the management of chronic kidney disease (CKD). | Healthcare & Biotech | Portfolio page | ||
| Phathom Pharmaceuticals is a biopharmaceutical company committed to transforming the treatment landscape and improving the lives of patients suffering from acid-related gastrointestinal (GI) disorders. | Healthcare & Biotech | Portfolio page | ||
| R1 Therapeutics is developing innovative first-in-class therapies for patients with kidney disease, starting with lead asset AP306 for the treatment of hyperphosphatemia in patients with chronic kidney disease. | Healthcare & Biotech | Mar 2026Series A | Funding round | |
| Redx is a clinical-stage biotechnology company focused on the development of novel, small molecule, targeted medicines for the treatment of fibrotic disease | Healthcare & Biotech | Portfolio page | ||
| Solve Therapeutics is developing novel antibody-drug conjugates for cancer treatment. | Healthcare & Biotech | Nov 2025Round | Page + round | |
| Timberlyne Therapeutics is a clinical-stage biopharmaceutical company focused on the development and commercialization of transformational therapies for autoimmune diseases. | Healthcare & Biotech | Portfolio page |
About this data
site last read 11 Nov 2026- Site
- abingworth.com
- Last read
- 11 Nov 2026
- Watching since
- 6 Nov 2026
- Rounds since
- 16 Apr 2025
- Companies checked
- 21
Rates come from what VCinfo has observed since observation_start. Firms tend to remove companies that closed, so early rates understate reality. A company leaving a portfolio page does not mean it closed or exited. An unreachable site means our checks failed, nothing more.
Get Abingworth's profile as data
Pull Abingworth's portfolio, co-investors and changes through one API key or MCP, open every portfolio row, compare it with other firms, and get an email when it adds a company or files a fund.
Work email, sign-in link by email. Already have an account? Log in- Ask AI5 plain-English investor searches a day
- Full listsEvery portfolio row and two-firm overlap
- API and MCP100 REST or MCP calls a month, one key
- AlertsFollow 5 investors for portfolio and fund changes
$ curl -H "X-API-Key: YOUR_KEY" \
https://api.vcinfo.io/v1/firms/abingworth.com
# also
GET /v1/firms/abingworth.com/portfolio
GET /v1/firms/abingworth.com/coinvestors
GET /v1/firms/abingworth.com/news